A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adults

Conditions: Respiratory Syncytial Virus Infections Interventions: Biological: Bivalent RSV Vaccine (IN006); Biological: Placebo Sponsors: Shenzhen Shenxin Biotechnology Co., Ltd Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials